Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | Trametinib | 1 | 72 | 1.0 | 1818.5 | 4308.0 | 1295.5 | 0.0 | 0.216 | 0.422 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | XL147 | 1 | 72 | 1.0 | 4168.0 | 4362.8 | 1295.5 | 0.0 | 0.949 | 0.955 | 1.752 | HCC38 XL147 0 1 72 |
| BT-20 | GDC-0980 | 2 | 72 | 1.0 | 611.3 | 3217.8 | 1018.6 | 0.0 | -0.265 | 0.190 | 1.659 | BT20 GDC0980 0 2 |
| BT-549 | BX-912 | 1 | 72 | 1.0 | 3078.0 | 5561.8 | 1554.9 | 0.0 | 0.450 | 0.553 | 1.839 | BT549 BX912 0 1 72 |
| BT-20 | AZD8055 | 3 | 72 | 1.0 | 616.8 | 3441.0 | 586.9 | 0.0 | 0.020 | 0.179 | 2.552 | BT20 AZD8055 0 3 |
| HCC38 | AZD8055 | 2 | 72 | 1.0 | 968.3 | 3018.8 | 690.5 | 0.0 | 0.172 | 0.321 | 2.128 | HCC38 AZD8055 0 2 72 |
| HCC38 | Dactolisib | 2 | 72 | 1.0 | 726.5 | 3001.5 | 690.5 | 0.0 | 0.024 | 0.242 | 2.120 | HCC38 BEZ235 0 2 72 |
| BT-20 | Everolimus | 1 | 72 | 1.0 | 3532.8 | 5781.0 | 1443.3 | 0.0 | 0.564 | 0.611 | 2.002 | BT20 Everolimus 0 1 |
| BT-549 | KIN001-244 | 2 | 72 | 1.0 | 4590.5 | 4727.5 | 1249.6 | 0.0 | 0.970 | 0.971 | 1.920 | BT549 KIN001-244 0 2 72 |
| BT-20 | TGX221 | 1 | 72 | 1.0 | 5819.3 | 5723.8 | 1443.3 | 0.0 | 1.020 | 1.020 | 1.988 | BT20 TGX221 0 1 |
| BT-20 | Omipalisib | 2 | 72 | 1.0 | 235.0 | 3349.0 | 1018.6 | 0.0 | -0.574 | 0.070 | 1.717 | BT20 GSK458 0 2 |
| BT-549 | PIK-93 | 2 | 72 | 1.0 | 4329.3 | 4941.3 | 1249.6 | 0.0 | 0.871 | 0.876 | 1.983 | BT549 PIK93 0 2 72 |
| BT-549 | Sirolimus | 2 | 72 | 1.0 | 2849.8 | 4441.5 | 1249.6 | 0.0 | 0.569 | 0.642 | 1.830 | BT549 Rapamycin 0 2 72 |
| HCC38 | KIN001-244 | 2 | 72 | 1.0 | 3137.5 | 3196.0 | 690.5 | 0.0 | 0.983 | 0.982 | 2.210 | HCC38 KIN001-244 0 2 72 |
| HCC38 | MK2206 | 2 | 72 | 1.0 | 2629.3 | 3083.8 | 690.5 | 0.0 | 0.858 | 0.853 | 2.159 | HCC38 MK2206 0 2 72 |
| BT-20 | Sirolimus | 3 | 72 | 1.0 | 1499.8 | 3288.5 | 586.9 | 0.0 | 0.458 | 0.456 | 2.486 | BT20 Rapamycin 0 3 |
| HCC38 | Sirolimus | 2 | 72 | 1.0 | 1847.0 | 2971.8 | 690.5 | 0.0 | 0.596 | 0.622 | 2.105 | HCC38 Rapamycin 0 2 72 |
| BT-20 | Trametinib | 2 | 72 | 1.0 | 1967.5 | 3363.5 | 1018.6 | 0.0 | 0.465 | 0.585 | 1.723 | BT20 Trametinib 0 2 |
| BT-20 | KIN001-244 | 2 | 72 | 1.0 | 3085.0 | 3407.5 | 1018.6 | 0.0 | 0.889 | 0.905 | 1.742 | BT20 KIN001-244 0 2 |
| BT-549 | CAL-101 | 1 | 72 | 1.0 | 4907.3 | 5381.3 | 1554.9 | 0.0 | 0.900 | 0.912 | 1.791 | BT549 CAL101 0 1 72 |
| BT-20 | Dactolisib | 3 | 72 | 1.0 | 727.5 | 3141.3 | 586.9 | 0.0 | 0.093 | 0.232 | 2.420 | BT20 BEZ235 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 1.0 | 2595.5 | 3394.0 | 586.9 | 0.0 | 0.799 | 0.765 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | PI103 | 2 | 72 | 1.0 | 929.3 | 3367.0 | 1018.6 | 0.0 | -0.052 | 0.276 | 1.725 | BT20 PI103 0 2 |
| HCC1806 | Omipalisib | 1 | 72 | 1.0 | 1813.3 | 11840.0 | 1742.8 | 0.0 | 0.014 | 0.153 | 2.764 | HCC1806 GSK458 0 1 72 |
| HCC1806 | GDC-0980 | 1 | 72 | 1.0 | 5800.0 | 11293.0 | 1742.8 | 0.0 | 0.562 | 0.514 | 2.696 | HCC1806 GDC0980 0 1 72 |